featured
Ramucirumab vs Placebo in Combination With Second-Line FOLFIRI in Patients With Metastatic Colorectal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology